
The results support the potential for treatment de-escalation after hysterectomy for women with early-stage, intermediate-risk cervical cancer.

The results support the potential for treatment de-escalation after hysterectomy for women with early-stage, intermediate-risk cervical cancer.

The CAR-T treatment GLPG5101 received the FDA's RMAT designation by showing promising efficacy with rapid delivery and low toxicity in mantle cell lymphoma.

A phase 3 study shows Cylembio combined with pembrolizumab improves progression-free survival in advanced melanoma, highlighting its potential as a treatment option.

The vaccine ELI-002 2P showed favorable relapse-free survival and overall survival in patients with pancreatic and colorectal cancer, particularly if they had strong T-cell responses.

New research reveals that combining talazoparib with enzalutamide significantly enhances survival rates in metastatic prostate cancer patients, regardless of genetic factors.

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive bladder cancer patients ineligible for cisplatin.

A phase 1/2 trial reveals sacituzumab tirumotecan shows manageable toxicity and promising antitumor activity in patients with advanced solid tumors.

The FDA accepts a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling potential breakthroughs in treatment.

New data reveals sugemalimab significantly enhances survival rates in metastatic non–small cell lung cancer, establishing it as a key first-line treatment option.

The NCCN added critical guidance on Lambert-Eaton myasthenic syndrome to its recommendation for the diagnosis and treatment of small cell lung cancer.

Discover the latest breakthroughs in oncology, including FDA approvals and innovative therapies reshaping cancer treatment landscapes.

Zongertinib gains FDA approval for advanced NSCLC with HER2 mutations, showcasing promising efficacy and safety in clinical trials.

ProteinQure's PQ203, a novel peptide drug conjugate, gains FDA fast track designation for advanced triple-negative breast cancer clinical trials in North America.

Epcoritamab shows promising results in treating relapsed follicular lymphoma, with FDA priority review for a groundbreaking combination therapy.

A study reveals real-world outcomes of neoadjuvant immune checkpoint inhibitors in nonmetastatic colon cancer, highlighting lower efficacy and increased toxicity.

Despite its increased use, immunoglobulin replacement therapy does not lower the risk of serious infection in patients with chronic lymphocytic leukemia.

During a live event, Tony Philip, MD, recommended tailored imaging intervals and avoiding surgery and radiation for desmoid tumors.

Roxadustat advances as a promising oral treatment for anemia in lower-risk myelodysplastic syndromes, targeting high transfusion dependency.

The FDA approves the Embrace Hydrogel Embolic System, offering a groundbreaking treatment for hypervascular tumors in interventional oncology.

FDA accepts a new formulation of piflufolastat F 18, enhancing prostate cancer imaging access and efficiency, with a target action date of March 2026.

Updated data from the BEXMAB study reveals a significant increase in complete remission rates for patients with high-risk myelodysplastic syndrome treated with bexmarilimab.

The FDA fast-tracks birelentinib, a dual inhibitor for relapsed CLL/SLL, promising new hope for patients facing treatment resistance.

FDA expands tocilizumab-anoh's indication for treating cytokine release syndrome, enhancing treatment options for patients undergoing CAR T-cell therapy.

A new FDA-approved trial explores innovative treatments for recurrent glioblastoma, offering hope for patients facing this aggressive brain cancer.

The RESONATE-2 trial reveals ibrutinib's long-term efficacy and safety in treating CLL/SLL, especially for high-risk patients, over nearly a decade.

Akeso initiates a pivotal trial for cadonilimab and lenvatinib, targeting advanced liver cancer resistant to PD-1 therapy, addressing urgent treatment needs.

FDA accelerates approval of dordaviprone, the first targeted therapy for aggressive diffuse midline glioma, offering hope for patients with H3 K27M mutation.

The FDA issued a complete response letter to the odronextamab application in follicular lymphoma, rejecting the drug for a second time in this patient population.

Eftilagimod alfa shows promise as a novel immunotherapy for head and neck cancer patients with low PD-L1 expression, offering new treatment hope.

Hemispherian's GLIX1 gains FDA approval for glioblastoma trials, promising a novel therapy targeting DNA repair in tumor cells.